CG-200745 is a potent inhibitor of HDAC. CG200745 induces apoptosis and also inhibits the deacetylation of histone H3 and tubulin.

CG200745 induces the accumulation of p53. It promotes p53-dependent transactivation, and it also enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins [1,2]. CG-200745 (0-10 μM; 48 hours) reduces the Calu6 cells proliferation to 40% of untreated cells. CG-200745 (0-10 μM; 1-24 hours) treatment with low concentration significantly increases the acetylation of histone H3 and H4 in Calu6 cells at various sites in a time-dependent manner up to 24 hours after treatment. CG-200745 (3 μM; 1-24 hours) significantly increases Calu6 cells proportion in the G2/M phase (69%) [3].

CG-200745 (p.o.; 30?mg/kg/day; for 7 days) weaken inflammatory cytokines, adhesion molecules, oxidative stress in UUO kidneys [4].

936221-33-9

C24H33N3O4

427.54

CG-200745;Ivaltinostat

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years